Skip to main content

How To reduce Alzheimer’s risk

Could Viagra reduce Alzheimer’s risk?


Written by James Kingsland on December 8, 2021 
Close up of two Pfizer Viagra tabletsShare on Pinterest
A new study investigates whether Viagra might influence Alzheimer’s disease. Simon Dawson/Bloomberg via Getty Images
  • Using genetic and other biological data, researchers recently concluded that Viagra (sildenafil) might influence Alzheimer’s disease.
  • When they analyzed insurance claims for prescriptions, they found that sildenafil scrips were associated with a 69% reduced risk of Alzheimer’s in claimants.
  • Laboratory tests on nerve cells from people with Alzheimer’s supported the notion that sildenafil may treat the disease.
  • However, the researchers emphasize that only clinical trials can provide definitive proof that sildenafil is an effective treatment for Alzheimer’s.

Doctors prescribe sildenafil — popularly known by its brand name, Viagra — to treat erectile dysfunction and pulmonary arterial hypertension, which refers to high blood pressure in the lungs.

However, several studiesTrusted Source in mice, and a few pilot studiesTrusted Source in humans, have hinted that sildenafil could also treat Alzheimer’s disease.

A new study has now provided biological and population-based evidence to support the idea that the drug may help prevent and treat the disease.

“Developing drugs for diseases, like Alzheimer’s, which attack the brain, is a costly process and can take many years,” Dr. Susan Kohlhaas, Ph.D., director of research at Alzheimer’s Research UK in the United Kingdom, told Medical News Today.

“Being able to repurpose a drug already licensed for other health conditions could help speed up the drug discovery process and bring about life-changing dementia treatments sooner,” she said.

The study, led by the Genomic Medicine Institute at the Cleveland Clinic in Cleveland, OH, appears in Nature AgingTrusted Source.

In Alzheimer’s disease, the most common form of dementia, the death of brain cells causes progressive memory loss and cognitive decline.

Due to our aging population, scientists predict that by 2050, 13.8 million people in the United States alone will have Alzheimer’s.

The main hallmarksTrusted Source of the disease in the brain are plaques of a protein called beta-amyloid and fibrous tangles of tau, another protein.

So far, however, clinical trials of drugs and vaccines that target the two proteins have met with disappointingTrusted Source results.

A complex interplay of genes and environmental factors causes Alzheimer’s.

To predict which existing drugs could provide new treatments, the researchers used a computational model that incorporates data about the disease’s genetics and the involved networks of metabolic pathways.

In particular, they focused on interactions between proteins in networks that play a part in creating both beta-amyloid and tau.

Next, they generated “network proximity measures” for over 1,600 approved drugs according to how closely they interact with these Alzheimer’s-related networks.

This allowed the scientists to narrow down the field to 66 drugs that could potentially treat the disease. Taking into account other considerations, such as promising results from experiments in animal models of Alzheimer’s, sildenafil emerged as the most promising candidate.

The researchers investigated further by analyzing insurance claims for prescriptions from 7.23 million people in the U.S.

Overall, they discovered that claimants who were prescribed sildenafil had a 69% reduced risk of Alzheimer’s over the following 6 years.

The association remained statistically significant after accounting for other factors that influence Alzheimer’s risk, such as sex, ethnic group, and other medical conditions. These conditions included type 2 diabetes, high blood pressure, coronary artery disease, and mild cognitive impairment.

Finally, to confirm sildenafil that can affect the underlying mechanism of Alzheimer’s, the researchers tested the drug in the lab on nerve cells that came from individuals with the disease.

They found that sildenafil promoted the growth of new nerve projections and decreased tau accumulation in the cells.

Researchers often use tau as a biomarker to gauge the progress of the disease in animal models and people.

Alzheimer’s

The authors caution that their study design cannot demonstrate a causal relationship between using a particular drug and the risk of Alzheimer’s.

They say there may be hidden confounding factors that influence not only Alzheimer’s risk but also the likelihood of sildenafil use.

Possible confounding factors, which the insurance data did not include, include education level and socioeconomic status.

However, there was no significant difference in total annual prescription costs between sildenafil users and nonusers, suggesting the two groups did not differ in terms of wealth.

The authors believe their lab results support the conclusion that sildenafil is a potential treatment.

“[W]e don’t think the socioeconomic status will drive our findings, as we further validated our findings in [Alzheimer’s] patient-derived [nerve cell] models as well,” senior author Feixiong Cheng, Ph.D., told MNT.

The authors further note that the insurance data did not include genetic information, such as whether claimants had a particular version of the apolipoprotein E geneTrusted Source, which increases Alzheimer’s risk and affects patients’ responses to treatment.

In addition, healthcare professionals mostly prescribe sildenafil to males, so the study was unable to determine any possible benefits in females with regard to Alzheimer’s risk.

“While the researchers did look at the effect of sildenafil on females, there isn’t enough information to be able to accurately draw conclusions about its effect in females, which account for the majority of Alzheimer’s cases worldwide,” said Dr. Kohlhaas.

“Importantly, this research doesn’t prove that sildenafil is responsible for reducing dementia risk or that it slows or stops the disease,” she said.

“The only way to test this would be in a large-scale clinical trial measuring sildenafil’s effects against the usual standard of care.”

The authors conclude:

“Taken together, the association between sildenafil usage and decreased incidence of [Alzheimer’s disease] does not establish causality or its direction, and our results, therefore, warrant rigorous clinical trial testing of the treatment efficacy of sildenafil in patients with [Alzheimer’s disease], inclusive of both sexes and controlled by placebo.”

“We are planning a mechanistic trial and biomarker-guided phase 2 trial in the next step to further verify [the] clinical benefit of sildenafil in early [Alzheimer’s disease] patients,” Dr. Cheng told



skunty empire

Comments

TRENDING

Felicity Cloake’s hot cross buns recipe

Susan Boyle 'Is Replaced on Britain's Got Talent: The Champions'

Do you Need A visa To Visit Kenya

Lucrative Pop Phenomenon

How to prepare Miso Chicken

Week 14 college football rankings: Collecting new top 25s as they come out

Hero' officer who swapped with French supermarket hostage dies

Popular posts from this blog

Felicity Cloake’s hot cross buns recipe

New post Felicity Cloake’s hot cross buns recipe Felicity Cloake’s step-by-step approach to the quintessential Easter treat fun of making your own. They may take some time to prep but are all part of the pre-Easter ritual. Prep 3 hr Bake 25 min Makes 16 200ml milk , plus a little extra for glazing 3 cardamom pods 1 cinnamon stick 2 cloves ¼ tsp grated nutmeg 1 pinch saffron 450g strong white flour 7g sachet fast-action yeast 100g cold butter 50g golden caster sugar , plus 1 tbsp extra for the syrup ½ tsp salt ½ tsp ground ginger 3 eggs 150g currants 50g mixed peel 3 tbsp plain flour 1 Infuse the milk Pour the milk into a small pan. Squash the cardamom pods with the back of a knife, then add to the milk with the cinnamon, cloves, nutmeg and saffron. Heat gently to a simmer, then take the pan off the heat and leave the milk to infuse for an hour.   All Dfg 3 Make the dough Lightly beat two of the eggs, then pour these into the...

Susan Boyle 'Is Replaced on Britain's Got Talent: The Champions'

Susan Boyle 'Is Replaced on Britain's Got Talent: The Champions' Susan Boyle has been reportedly been replaced on Britain’s Got Talent: The Champions (Picture: Rex) Susan Boyle is reportedly being replaced on  Britain’s Got Talent : The Champions by 2011 winner Jai MacDowall. SuBo’s place on the BGT spin-off series had been in jeopardy due to her packed schedule, so bosses chose to recruit another contestant, sources claimed. Scottish singer Jai, 33, was apparently brought in by producers after successfully auditioning against 2014 finalist Lucy Kay, 30. ‘They didn’t want to be short of contestants and SuBo was looking unlikely to confirm her appearance,’ a source told  . ‘Jai was ecstatic and will be putting his heart into the show, in the hope of making it right to the end.’ Metro.co.uk has contacted reps for ITV and Susan for comment. Jai McDowall, who won the 2011 series, is apparently replacing her (Picture: Getty) Susan, who has sold m...

What to watch in the Americas today

What to watch in the Americas today Expansion: The US Federal Reserve will get a gander at its leaned toward expansion measure today with the arrival of individual utilization consumptions (PCE) information. The PCE value record barring food and energy costs was up 4.1 percent in October, the biggest leap since the 1990s. Financial analysts surveyed by FactSet expect a considerably greater yearly ascent in November of 4.6 percent. The report will likewise detail the most recent information on close to home spending and pay. Estimate show that both are probably going to have climbed month-to-month. Jobless cases: Economists have anticipated that new joblessness filings ticked lower last week to 205,000 from the 206,000 every week sooner. That would mean the speed of jobless cases stayed close to pre-pandemic levels, a sign that organizations have kept away from lay-offs while attempting to staff up in the midst of the recuperation. Tough merchandise: The Census Bureau will distribute it...

Do you Need A visa To Visit Kenya

  Kenya has announced the removal of visa requirements for all visitors, starting in January.  President William Ruto stated that a digital platform has been developed to provide electronic travel authorization, eliminating the need for a visa. This decision is part of Kenya's efforts to promote tourism and facilitate easier travel for visitors. The move is also in line with the country's plan to end all visa requirements for visitors from other African countries by 2024 This significant change in visa policy is expected to have a positive impact on tourism and travel to Kenya. It reflects the country's commitment to enhancing its openness and accessibility to visitors from around the world, particularly from the African continent. The removal of visa requirements is likely to contribute to the growth of the tourism sector and strengthen Kenya's position as a key destination for travelers.  The new policy aligns with President Ruto's vision of promoting visa-free tr...